The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

BACKGROUND: Gefitinib, as the first epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC), has been proved to significantly improve the progression-free survival (PFS) in the first-line setting but suffers fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhonghan, Luo, Fan, Zhang, Yang, Ma, Yuxiang, Hong, Shaodong, Yang, Yunpeng, Fang, Wenfeng, Huang, Yan, Zhang, Li, Zhao, Hongyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839103/
https://www.ncbi.nlm.nih.gov/pubmed/31699150
http://dx.doi.org/10.1186/s40880-019-0414-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839103/
https://www.ncbi.nlm.nih.gov/pubmed/31699150
http://dx.doi.org/10.1186/s40880-019-0414-4

Ejemplares similares